Weight Loss Drugs: A Mixed Bag

A recent meta-analysis has brought a rather inconvenient aspect of weight loss to light. While willpower does play a role, the pharmaceutical industry wants us to overlook that—after all, it’s more profitable for them.

The argument that obesity mainly stems from genetics or environmental factors has been a staple for fat-positive advocates for years. Companies like Novo Nordisk and Eli Lilly are ramping up marketing for powerful new drugs that have, surprisingly, origins in lizard venom.

On average, those who stop using weight-loss medications regain weight at a rate of about 0.4 kilograms monthly—roughly 10 pounds a year. It’s quite alarming.

The market is expanding rapidly. About 1 in 8 American adults now resort to weight loss medications, but that figure still sits below its potential peak. With around 70% or more of U.S. adults categorized as overweight or obese, there’s a significant opportunity for growth.

Tablet Innovations

So, what’s next? It’s pretty clear: as ways to deliver these drugs evolve—especially with tablets—adoption rates are likely to soar. Not everyone is fond of needles, and tablets are easier to take.

Recently, the FDA approved a tablet version of Wegovy, appropriately dubbed the Wegovy Pill. Other competing drugs like Munjaro are also queued for release this year.

Not long ago, I speculated that a producer of weight-loss drugs could become the world’s largest company in the next decade. Currently, Novo Nordisk, the Danish producer of Wegovy and Ozempic, is already the most valuable company in Europe, with a market cap around $570 billion—significantly higher than Denmark’s entire GDP. I think I need to re-evaluate that thought. Correcting for results, side effects, and costs will be paramount for any pharmaceutical company aiming for the top.

There are over a billion people classified as obese worldwide. There’s no solid reason to think we couldn’t provide them all with a daily pill.

Questions of Efficacy

Returning to that meta-study, one big question lingers: what happens when patients discontinue these drugs? Do they keep shedding pounds, or does the weight come rushing back?

Unfortunately, many users abandon these medications relatively quickly. About 50% stop within a year, often due to various adverse effects—like gastrointestinal issues, vision changes, or even costs. In rare cases, the outcome can be severe.

The aftermath of stopping is crucial. If users regain weight, many find themselves in an endless cycle, needing to take these drugs potentially for decades to avoid relapse. Pharmaceutical executives aren’t usually keen to confront this reality, though some have acknowledged it.

Habit Formation Challenges

The researchers behind the meta-study posed a critical question: how does the cessation of weight-loss drugs compare to quitting traditional methods like diet and exercise?

The stark difference is evident. Individuals who stop these medications regain weight at a rate four times faster than those who discontinue dieting or exercising. On average, that translates to about 0.4 kg a month or 10 pounds yearly.

This isn’t just a fluke; it’s more straightforward than it seems. Pills don’t instill habits. Dieting and exercising are what build enduring behaviors. With medication, the suppression of appetite is chemical and doesn’t lead to skill development. Once the drug is out of the system, the user is often left with the same reserves of willpower as before. Current studies indicate that the effects on hormonal signaling, brain chemistry, and metabolism vanish with the medication.

Even if those following traditional weight-loss methods experience relapses, the habits they form can improve their overall mental well-being. That’s something, right?

While it’s true that weight-loss medications can be beneficial—especially for severely obese individuals—this might be their primary effective solution. To truly combat chronic diseases, though, we can’t neglect the persistent truths: sustainable weight loss hinges on choices, habits, and personal attitudes, and it won’t happen without a supportive food environment that makes good choices more accessible. Medications can help facilitate those changes, but they can’t completely replace the need for them.